STREAM is a collaboration of researchers who share a common set of principles about the goals and methods for studying clinical translation. We apply empirical and philosophical tools for addressing scientific, ethical, and policy challenges in the development and translation of health technologies. Our members work in ethics, epidemiology, biology, psychology, and various medical specialties. The network is centered at McGill University, and has affiliates throughout North America and abroad.
STREAM is inviting applications for a postdoctoral research fellow (PDF). The position requires a background a background in clinical trials or ethics. The project will examine how risk, benefit, burdens, and clinical hypotheses evolve as new drugs are developed- and whether there are ways to improve efficiencies in clinical development. The project will also apply forecast methods.
Latest STREAM research covered on NPR’s All Things Considered (read here or listen here), and appears in the news briefs of Nature's The week in science: 30 June–6 July 2017. You can also check out the original paper in PLOS Biology, take a look at our leaderboard, or read Dr. Kimmelman's blog post on the back story behind the project.
Dr. Kimmelman was also interviewed for CBC's Second Opinion
Jonathan Kimmelman quoted in MIT Technology Review
Jonathan Kimmelman gives his take on underreporting of adverse events in trial reports: Des effets secondaires des médicaments restent absents des publications scientifiques in Le Devoir
Benjamin D, Mandel D, Kimmelman J. Can cancer researchers accurately judge whether preclinical reports will reproduce? PLOS Biology June 29, 2017.
Hakala A, Fergusson D, Kimmelman J. Nonpublication of trial results for new neurological drugs: A systematic review. Annals of Neurology, 2017.
Kimmelman J, Resnik DB, Peppercorn J, Ratain MJ. Burdensome Research Procedures in Trials: Why Less is More. JNCI. 2017. DOI:https://doi.org/10.1093/jnci/djw315
Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J. Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLOS Biology February 3, 2017.